Tag Archive for: wesley hospital urologist brisbane

Renal cysts: when to reassure, when to investigate and when to treat

/0 Comments/in , /by

Renal cysts are fluid-filled sacs within or on the kidney. Finding a “cyst” on a scan can be worrying, but many are harmless. The important questions are whether the cyst has a simple or complex appearance, whether it is causing symptoms, and whether it affects urine drainage or kidney function.

A large simple cyst is not automatically cancerous, and a small complex cyst is not automatically harmless. Imaging features and the clinical situation guide management.

What types of renal cysts are there?

Simple cysts have a thin, smooth wall and contain fluid. They become more common with age and usually cause no symptoms or loss of kidney function. Most need no treatment.[1]

Complex cystic masses have additional features, such as internal partitions called septa, thickened walls or tissue nodules. “Complex” describes their appearance; it does not establish a cancer diagnosis.[2]

Parapelvic cysts lie beside the renal pelvis, the funnel that collects urine before it enters the ureter. Their location can make diagnosis and treatment more difficult.[6]

Polycystic kidney disease is a separate condition, often inherited, in which multiple cysts may enlarge the kidneys and affect kidney function. Numerous cysts in both kidneys, especially with a family history, merit assessment for cystic kidney disease rather than being assumed to be ordinary simple cysts.[9]

How do renal cysts present?

Most simple cysts are discovered incidentally during an ultrasound, CT or MRI performed for another reason.

Occasionally, a cyst causes a dull ache in the flank or back, pressure or discomfort, or obstruction to urine drainage. Bleeding, infection or rupture can cause more acute symptoms. Fever with flank pain may indicate infection.[1]

Pain and blood in the urine have many possible causes, including stones and other urinary tract conditions. Finding a cyst does not prove that it caused the symptoms. Visible blood in the urine should be assessed rather than attributed to a known cyst.

What investigations are needed?

Ultrasound often identifies an uncomplicated simple cyst. If the lesion is uncertain or complex, a dedicated contrast-enhanced CT or MRI can assess its wall, septa and any solid tissue. Contrast-enhanced ultrasound is another option in centres with appropriate expertise.[3]

An important finding is enhancement: tissue becomes brighter after contrast, indicating a blood supply. Enhancement in thickened or irregular tissue or a nodule raises concern.

Urine testing and blood tests for kidney function may be appropriate. Infection symptoms may require a urine culture. Contrast choices are individualised according to kidney function, allergies and other circumstances.

Ordinary ultrasound alone may not adequately classify a complex cyst. A radiology report should ideally state which version of the Bosniak classification has been used.[2,3]

Bosniak classification: understanding the scan report

The Bosniak system groups cystic renal masses by imaging appearance. The 2019 version incorporates CT and MRI criteria. It estimates concern for malignancy; it is not a cancer stage or a substitute for specialist assessment.[2]

Category Simplified meaning Usual approach
I Simple fluid-filled cyst with a thin, smooth wall Benign; no routine follow-up if confidently classified
II Benign features, such as a few thin septa or certain non-enhancing blood/protein-containing cysts Usually no routine follow-up
IIF More septa or mild smooth thickening; “F” means follow-up Scheduled imaging to check for change
III Enhancing thick or irregular walls or septa Indeterminate; specialist discussion of surveillance or treatment
IV An enhancing tissue nodule Strong concern for cancer; specialist assessment and treatment planning

This table is deliberately simplified. Calcification or blood within a cyst does not by itself establish cancer. The pattern of enhancement and tissue architecture matters.[2,3]

When should cancer be a concern?

Concern increases with enhancing nodules, irregular or thick enhancing walls/septa, or progression to a more suspicious category on follow-up.

Bosniak III masses include both benign and malignant lesions. Bosniak IV masses have a high likelihood of malignancy. Published percentages vary with the classification version and which patients undergo surgery, so a single percentage should not be treated as an individual prediction.[3,4]

Absence of symptoms does not exclude cancer. Conversely, enlargement of an otherwise simple cyst does not alone prove malignant change.

Follow-up and active surveillance

For Bosniak IIF lesions, the Canadian Urological Association suggests imaging at 6–12 months during the first year, then annually if stable, for a total of five years without progression.

Its 2023 guideline also supports active surveillance as a preferred option for selected Bosniak III/IV masses measuring 2 cm or less; surveillance or surgery for those measuring 2–4 cm; and surgery generally for those larger than 4 cm. These recommendations have limited-certainty evidence and require shared decision-making.[4]

Other guidelines differ in emphasis. The EAU allows surveillance for selected Bosniak III lesions and generally manages Bosniak IV lesions as localised kidney cancer.[8] Age, overall health, kidney function, imaging features and patient preferences all matter.

Surveillance means planned scans and reassessment, with treatment considered if concern increases. Biopsy may help when there is a targetable solid component and the result would change management; sampling a mainly fluid-filled lesion often has a low diagnostic yield.[4]

When should a benign cyst be treated?

Treatment may be considered for persistent symptoms convincingly attributable to the cyst, obstruction, or complications such as infection. There is no universal size threshold requiring treatment for a confidently benign simple cyst.[1]

Before intervention, the team should establish that the lesion is benign and discuss whether treatment is likely to relieve the symptoms.

Treatment options

Interventional radiology: aspiration and sclerotherapy

An interventional radiologist can use ultrasound or CT to guide a needle or catheter into a suitable simple cyst. The fluid is drained, usually under local anaesthetic, sometimes with sedation.

Aspiration alone can provide temporary relief, but the cyst may refill. Sclerotherapy adds an agent to damage the fluid-producing lining and reduce recurrence. The team must exclude communication with the urine collecting system before using a sclerosant.

A systematic review of 57 studies reported treatment success in approximately 88% of patients receiving aspiration with sclerotherapy, defined as symptom resolution together with more than 50% cyst-size reduction. Techniques and study quality varied; this is not a guarantee for an individual patient.[5]

Risks include pain, bleeding, infection, leakage of the agent, injury to nearby structures and recurrence. Repeat treatment may be needed.

Laparoscopic cyst deroofing

Deroofing, also called decortication, removes part of the cyst wall so it cannot readily reform as a closed sac. The removed tissue is usually sent for pathology.

Performed through small incisions under general anaesthesia, it may suit large, accessible symptomatic cysts or cysts that recur after percutaneous treatment.

A comparative meta-analysis found lower treatment-failure rates with laparoscopic deroofing than aspiration with sclerotherapy, while percutaneous treatment generally involved shorter procedures, shorter hospital stays and fewer complications.[7]

Surgical risks include bleeding, infection, injury to nearby organs or the collecting system, urine leakage, persistent pain and recurrence. Recovery depends on the procedure and the patient’s health.

Robotic-assisted deroofing

Robotic assistance is another way to perform minimally invasive cyst surgery. It may help with dissection in selected cases, but the robot is operated by the surgeon. Its availability does not mean it is necessary or offers a better result for every cyst. Location, complexity, expertise and cost should guide the choice.[7]

If the cyst is suspicious for cancer

Simple drainage or deroofing is not an appropriate cancer operation. Management may involve surveillance, partial nephrectomy to remove the lesion while preserving kidney tissue, or occasionally removal of the whole kidney. Ablation may be considered in selected patients, although evidence for complex cystic lesions is limited.[4,8]

I no longer perform nephrectomies. If partial or radical nephrectomy is indicated, I will refer you to a colleague who performs this surgery.

Parapelvic cysts: a special situation

Parapelvic cysts are beside the kidney’s central urine collecting system and usually do not communicate with it. They can mimic hydronephrosis, a dilated collecting system, on ultrasound. Contrast imaging, sometimes including delayed images, can distinguish the two and show whether a cyst is compressing urine drainage.[6]

Many asymptomatic benign parapelvic cysts can be observed. Treatment may be considered when a cyst causes pain or demonstrable obstruction.

Options include carefully planned laparoscopic or robotic deroofing, or ureteroscopic internal drainage in selected cases. With ureteroscopy, a telescope passes through the urethra, bladder and ureter into the kidney; a laser opens the cyst into the collecting system. A temporary ureteric stent may be required. Published studies support feasibility, but long-term comparative evidence remains limited.[6,10]

Sclerotherapy is generally avoided for parapelvic cysts because leakage or inflammation near the collecting system can cause scarring and obstruction. Any proposed percutaneous approach requires specialist assessment; routine simple-cyst treatment should not be applied automatically.[6]

Their proximity to blood vessels and the collecting system also increases the technical difficulty of surgery. Risks include bleeding, urine leakage, infection, narrowing and recurrence.

When to seek prompt medical attention

Seek urgent assessment for severe flank pain with fever or rigors, significant bleeding or clots in the urine, difficulty passing urine, or pain accompanied by faintness or marked illness. Persistent visible blood in the urine also requires medical review.

References

  1. National Institute of Diabetes and Digestive and Kidney Diseases. Simple kidney cysts.
  2. Silverman SG, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019;292:475–488. Article.
  3. European Association of Urology. Renal Cell Carcinoma Guidelines: Diagnostic evaluation.
  4. Canadian Urological Association. 2023 update: Management of cystic renal lesions. Canadian Urological Association Journal. Guideline.
  5. Brown D, et al. Radiologically guided percutaneous aspiration and sclerotherapy of symptomatic simple renal cysts: a systematic review of outcomes. Abdominal Radiology. 2021. PubMed.
  6. Ureteroscopic management of asymptomatic and symptomatic simple parapelvic renal cysts. BMC Urology. 2015. Article.
  7. Comparison of aspiration with sclerotherapy and laparoscopic deroofing for the treatment of symptomatic simple renal cysts: a systematic review and meta-analysis. Updates in Surgery. 2021. PubMed.
  8. European Association of Urology. Renal Cell Carcinoma Guidelines: Epidemiology, aetiology and pathology and Disease management.
  9. NIDDK. What is polycystic kidney disease?.
  10. Transurethral flexible ureteroscopic incision and drainage with holmium laser in the treatment of parapelvic renal cysts. International Brazilian Journal of Urology. 2022. Article.

General patient education. Individual management depends on imaging findings, symptoms, kidney function and discussion with the treating team. Reviewed October 2026.

PUJ obstruction: when urine cannot drain freely from the kidney

/0 Comments/in , /by

Understanding pelvi-ureteric junction obstruction, its symptoms, investigations and treatment, including robotic-assisted pyeloplasty.

The kidneys produce urine, which collects in a funnel-shaped area called the renal pelvis before travelling down the ureter to the bladder. The pelvi-ureteric junction (PUJ) is where this funnel joins the ureter.

PUJ obstruction means urine does not pass freely through this junction. It is also called ureteropelvic junction obstruction, or UPJ obstruction. The collecting system can enlarge, a finding called hydronephrosis, and significant obstruction may eventually damage the affected kidney. However, a dilated collecting system does not automatically mean surgery is needed. Assessment must establish whether drainage is impaired and whether kidney function is at risk. [1,2]

What causes PUJ obstruction?

Some people are born with a short segment that is narrow or does not propel urine normally. Other anatomical causes include kinking or a ureter that joins the renal pelvis unusually high up. A blood vessel supplying the lower part of the kidney may cross the junction and contribute to compression. Seeing a crossing vessel on a scan does not, by itself, prove that it is causing obstruction.

A congenital problem may first become apparent in adulthood. Acquired narrowing can follow scarring, inflammation or previous surgery. Stones and other causes of upper urinary tract blockage must also be considered during investigation. [2,12]

How does it present?

Symptoms range from none at all to episodes of significant pain. Possible presentations include:

  • Aching or intermittent pain in the flank, the side of the back below the ribs.
  • Episodes of more severe pain, sometimes with nausea or vomiting.
  • Pain after a large fluid intake, when urine production increases.
  • Recurrent urinary infections, including infection of the kidney.
  • Blood in the urine or kidney stones.
  • An incidental finding of hydronephrosis on a scan.

Intermittent painful distension is sometimes called a Dietl’s crisis. These symptoms can also have other causes, so pain or blood in the urine should not simply be attributed to a known PUJ problem. [3,12]

Children may be diagnosed following an antenatal ultrasound. Childhood assessment and treatment decisions differ from those in adults and should involve a paediatric urology team. [3]

Which investigations are useful?

The investigation plan answers three questions: What does the anatomy look like? How well does each kidney function? Is urine drainage genuinely obstructed?

Urine and blood tests

Urine testing looks for blood and evidence of infection; a urine culture is useful when infection is suspected. Blood tests include creatinine and estimated glomerular filtration rate (eGFR). These assess overall kidney function, but can remain normal when the other kidney compensates for an affected kidney. [2,10]

Ultrasound

Ultrasound shows collecting-system dilatation and assesses the thickness of the kidney tissue. It is useful for follow-up because it does not involve radiation. Ultrasound alone cannot reliably establish the functional significance of a PUJ narrowing. [2,3]

CT or MR urography

CT urography can define the junction, identify stones and assess surrounding structures, including crossing vessels. The use of intravenous contrast depends on kidney function and other clinical factors.

MR urography is an alternative in selected patients, particularly when avoiding radiation is desirable. The choice of scan is individualised. [1,2]

MAG3 diuretic renogram

This nuclear medicine scan follows a small injected tracer through the kidneys. A diuretic, usually furosemide, helps assess drainage.

It measures:

  • Differential or split renal function: the proportion contributed by each kidney.
  • Drainage: how effectively tracer leaves the collecting system.

Interpretation considers the images, drainage curves, kidney function, hydration and bladder emptying. A slow drainage number alone is insufficient to diagnose clinically significant obstruction: a large collecting system or poorly functioning kidney can make interpretation difficult. [4]

Further tests in selected cases

A retrograde pyelogram introduces contrast into the ureter during a telescopic bladder examination. It can clarify anatomy when other imaging is incomplete. It is not routinely needed in every patient. [2]

Does every PUJ obstruction need treatment?

No. Observation can be appropriate when symptoms are absent or minor, kidney function is stable, and assessment does not suggest harmful obstruction. Monitoring may include symptoms, ultrasound and repeat functional imaging when indicated. The interval depends on the findings. [5]

Intervention is more likely to be recommended for persistent or troublesome symptoms, recurrent kidney infections, associated stones, or deteriorating function. Decisions use the overall clinical picture rather than the ultrasound appearance alone. [2]

What are the treatment options?

Option When it may be considered Main limitation
Observation Stable function with few symptoms Requires planned follow-up
Ureteric stent or nephrostomy Urgent drainage or temporary management Usually does not permanently correct the narrowing
Endopyelotomy or balloon dilatation Selected narrowings or recurrent obstruction Generally less durable than reconstructive repair
Pyeloplasty A significant obstruction requiring reconstruction Requires an operation and recovery

Temporary or emergency drainage

A ureteric stent passes internally from the kidney to the bladder. A nephrostomy drains the kidney through a tube placed through the skin of the back. These can relieve obstruction while infection is treated or definitive surgery is planned. [5,9]

An infected obstructed kidney is an emergency. Antibiotics may be needed together with urgent drainage. Definitive reconstruction is usually considered after the acute problem has been controlled. [9,10]

Endoscopic treatment

Endopyelotomy opens the narrowed segment from inside the urinary tract; balloon dilatation stretches it. Suitability depends on the anatomy, kidney function and previous treatment.

A large observational study found more repeat procedures after endopyelotomy than after pyeloplasty. Because patients were not randomly assigned to treatment, these results inform discussion but cannot predict an individual outcome. [1,6]

Robotic-assisted pyeloplasty: how is the repair performed?

Pyeloplasty reconstructs the junction to improve drainage. It can be performed through an open incision, conventional laparoscopic keyhole surgery, or robotic-assisted keyhole surgery.

The commonly used Anderson–Hynes dismembered pyeloplasty removes the narrowed segment. The surgeon opens the ureter more widely and stitches it back to the renal pelvis, creating a broader connection. Where a crossing vessel contributes to obstruction, the reconstruction can be positioned in front of it while preserving the vessel. [3]

During robotic-assisted surgery, the surgeon controls the instruments from a console. Magnified three-dimensional vision and articulated instruments assist dissection and suturing. The robot does not operate independently. [7]

A temporary internal stent is commonly placed to support healing. A bladder catheter and, sometimes, a drain may also be used initially. [5,7]

How successful is pyeloplasty, and is robotic surgery better?

Published literature commonly reports success above 90% for primary pyeloplasty, including open, laparoscopic and robotic approaches. Success may mean symptom relief, improved drainage or freedom from further surgery; definitions and follow-up differ between studies. These figures are not a guarantee. [1]

Robotic surgery is an established option, but it should not be presented as necessary or universally superior. Comparative research supports good outcomes with both conventional laparoscopic and robotic repair. Much of the evidence is observational, with differences in patient selection, surgical experience and follow-up. The choice should consider anatomy, surgeon expertise, availability and cost. [8]

The goals are to improve drainage, relieve attributable symptoms and preserve function. Previously lost kidney function may not fully recover, even after a technically successful operation. [11]

What are the risks and recovery expectations?

Risks include bleeding, infection, urine leakage, injury to nearby structures, recurrent narrowing, persistent pain and the need for another procedure. Anaesthetic complications and blood clots are also possible. Occasionally, conversion to open surgery is required. [5,7]

Stents can cause urinary frequency, urgency, blood in the urine and discomfort. Their removal must be arranged. Many patients leave hospital after approximately one to three days following uncomplicated keyhole repair, but recovery varies. Stents are often removed after four to six weeks. [5,7]

Follow-up may include ultrasound and a repeat drainage scan. Residual dilatation does not automatically mean the repair has failed; symptoms, drainage and function are assessed together. [4]

What if the kidney already functions poorly?

A low split-function result does not automatically mean the kidney must be removed. Selected patients may benefit from reconstruction or temporary drainage followed by reassessment. A systematic review found that pyeloplasty may relieve symptoms and stabilise function in poorly functioning kidneys, but the evidence was limited and recovery was unpredictable. [11]

Nephrectomy may be considered if the kidney has negligible useful function and causes ongoing pain or infection. This requires an individual discussion, including the health of the other kidney.

When should I seek urgent help?

Seek urgent medical assessment for fever or shaking chills with flank pain, severe uncontrolled pain, persistent vomiting, markedly reduced urine output, or feeling seriously unwell. The threshold for urgent assessment is particularly low if you have a single functioning kidney. [9,10]

This page provides general education and does not replace an individual assessment. The most suitable investigation and treatment depend on symptoms, anatomy, kidney function and overall health.

References

  1. Khan F, Ahmed K, Lee N, et al. Management of ureteropelvic junction obstruction in adults. Nature Reviews Urology. 2014;11:629–638. doi:10.1038/nrurol.2014.240.
  2. Borin JF. Ureteropelvic Junction Obstruction in Adults. Reviews in Urology. 2017;19(4):261–264. Full text.
  3. Oxford University Hospitals NHS Foundation Trust. PUJ Obstruction and Pyeloplasty: information for parents and carers. 2025. Patient leaflet. Used for congenital presentation and reconstruction principles; adult management differs.
  4. SNMMI/EANM. Procedure Standard/Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. 2018. Guideline.
  5. British Association of Urological Surgeons. Keyhole reconstruction of the kidney pelvis: laparoscopic pyeloplasty. 2023. Patient leaflet.
  6. Jacobs BL, Lai JC, Seelam R, et al. The comparative effectiveness of treatments for ureteropelvic junction obstruction. Urology. 2018;111:72–77. doi:10.1016/j.urology.2017.09.002.
  7. Kingston and Richmond NHS Foundation Trust. Kidney obstruction removal with robot. Patient information.
  8. Uhlig A, Uhlig J, Trojan L, et al. Surgical approaches for treatment of ureteropelvic junction obstruction—a systematic review and network meta-analysis. BMC Urology. 2019;19:112. doi:10.1186/s12894-019-0544-7.
  9. Guy’s and St Thomas’ NHS Foundation Trust. Nephrostomy catheter to drain urine from the kidney. Patient information.
  10. NHS. Hydronephrosis. Patient information.
  11. Pyeloplasty in Adults With Ureteropelvic Junction Obstruction in Poorly Functioning Kidneys: A Systematic Review. 2021. PubMed.
  12. Cleveland Clinic. Ureteropelvic Junction Obstruction. Reviewed 2024. Patient information.

Prepared October 2026.

Nephroptosis: is a “floating kidney” really a thing?

/0 Comments/in , /by

Can a kidney move enough to cause pain? Yes. Nephroptosis is a recognised anatomical condition, and in selected people it can cause symptoms. However, finding a mobile kidney does not automatically explain abdominal or flank pain. Establishing that connection is the central challenge, and the reason this condition has attracted controversy for more than a century.[1,2]

What is nephroptosis?

The kidneys normally sit towards the back of the abdomen, supported by surrounding fat and connective tissues. Some movement with breathing and changes in posture is normal.

Nephroptosis, also called a floating or mobile kidney, is conventionally defined as downward movement of more than 5 cm, or approximately two vertebral body heights, when a person moves from lying down to standing. A kidney can also rotate or move towards the midline.[3,4]

This differs from a congenital pelvic kidney, which developed in a lower position and stays there.

Published reports describe it more often in slim women and more often on the right, although men and people with other body types can be affected. Reduced support from surrounding fat is a proposed contributor. The true prevalence of symptomatic nephroptosis is uncertain; historical figures from people undergoing particular imaging tests should not be treated as estimates for the general population.[4]

How does it present?

Many mobile kidneys cause no symptoms. When symptoms occur, a suggestive pattern is:

  • An ache, dragging sensation or intermittent pain in the flank, the side between the lower ribs and hip, or abdomen.
  • Pain that becomes worse with standing, prolonged activity or particular positions.
  • Improvement when lying down.
  • Occasionally, a feeling of something moving within the abdomen.

Some patients experience more severe episodes with nausea or vomiting. Positional pain is a useful clue, but it does not establish the diagnosis.[2,5]

Possible mechanisms include intermittent kinking of the ureter, which drains urine to the bladder; stretching or twisting of the kidney’s blood vessels; or traction on nerves around the kidney. These mechanisms may differ between patients. Severe episodic pain from intermittent upper urinary tract obstruction is sometimes called a Dietl’s crisis, but that term is not specific to nephroptosis.[4,5]

Blood in the urine or urinary infections require investigation in their own right and should not simply be attributed to a mobile kidney.

How is the diagnosis made?

There are two separate questions: Does the kidney move excessively? And is that movement responsible for symptoms or impaired function?

1. Establish the symptom pattern and assess other causes

A consultation should explore where the pain occurs, its relationship to posture and activity, what relieves it, and associated urinary or gastrointestinal symptoms. Examination, urine testing and blood tests for kidney function help guide the investigation.

Other explanations include kidney stones, infection, obstruction at the junction between the kidney and ureter, musculoskeletal pain, and gastrointestinal or gynaecological conditions. Depending on the presentation, these may be more likely. A mobile kidney can coexist with an unrelated cause of pain.[2,3]

2. Compare imaging in different positions

A normal scan performed lying down may not exclude a problem that occurs when upright. If the clinical pattern raises suspicion, the imaging request should make the positional question explicit.[3,5]

Investigation What it can contribute Main limitation
Ultrasound lying down and upright Demonstrates movement and checks for changes in collecting-system dilatation Operator dependent; requires a deliberate positional examination
Doppler ultrasound in different positions May identify posture-related changes in renal blood flow An adjunct rather than a definitive test of the cause of pain
Positional nuclear medicine renal scan Assesses drainage and each kidney’s contribution to function; may reveal changes when upright Needs an appropriate protocol and careful interpretation
Intravenous urography with supine and erect images Historically used to measure kidney descent Used less often today; involves radiation and contrast
Selected positional CT urography Can clarify anatomy, rotation or medial movement Routine supine CT may miss positional mobility; repeat imaging adds radiation

The choice should be agreed with radiology or nuclear medicine. Not every centre routinely performs these protocols, and not every patient needs every test.[3,5,6]

3. Link the findings to the symptoms

Diagnostic confidence is stronger when the side and timing of the pain match the demonstrated movement, particularly if there is associated impaired drainage or blood flow. Nevertheless, some symptomatic patients have no demonstrable obstruction. The absence of obstruction does not conclusively exclude symptomatic nephroptosis, but it makes careful exclusion of other causes especially important.[3,4,6]

Normal overall kidney function does not, by itself, exclude an intermittent positional problem. Equally, descent beyond a measurement threshold is not sufficient justification for surgery.[2,5]

What are the treatment options?

Observation and symptom management

An incidentally discovered mobile kidney without symptoms or functional consequences generally does not require surgery.[5]

For mild symptoms, an individual plan may include modifying provoking activities, appropriate pain relief and reviewing other possible contributors. Abdominal supports, exercises and nutritional measures have been used historically, but convincing evidence that they reliably correct symptomatic nephroptosis is limited. They should not be presented as proven cures. Weight gain is not a universal recommendation.[1,2]

Nephropexy: fixing the kidney in position

Nephropexy repositions the kidney and secures it to surrounding tissues to limit excessive movement. It aims to preserve the kidney and relieve symptoms or positional impairment.

It may be considered when symptoms substantially affect daily life, nephroptosis has been demonstrated with appropriate imaging, other explanations have been reasonably excluded, and the evidence suggests a meaningful relationship between movement and symptoms. Documented positional obstruction or impaired perfusion strengthens the rationale.[2,3,5]

Modern surgery is usually laparoscopic, through the abdomen or behind it. Robotic assistance has also been described, but there is no convincing comparative evidence that it produces better outcomes than conventional laparoscopy for this condition. Fixation techniques vary, and some published methods use mesh while others use sutures.[3]

Open surgery is less commonly used. Percutaneous techniques, intended to stabilise the kidney through a tract and subsequent scarring, have also been reported. A recent report involved only four patients: such evidence is too limited to establish equivalence with laparoscopic surgery or support routine use.[7]

How effective is surgery, and what are the risks?

Small surgical series describe substantial improvement in selected patients. For example, a long-term study reported 13 patients assessed at a median of 5.9 years: 11 were completely satisfied and two moderately satisfied.[8]

That is encouraging, but it is not a reliable prediction for every patient. Small numbers, selection of patients, loss to follow-up and the absence of a non-operative comparison group limit what can be concluded. Fixing the kidney successfully does not guarantee that pain will disappear.[2,8]

Potential risks include bleeding, infection, injury to nearby organs, vessels or the urinary tract, anaesthetic complications, persistent or new pain, and recurrent kidney movement. If mesh is proposed, its specific benefits and risks should be discussed. Individual risks and expected recovery depend on the technique and the patient’s circumstances.

Why is nephroptosis controversial?

The controversy concerns which patients have symptoms caused by kidney mobility, and which benefit from treatment.

Historically, nephroptosis was blamed for a wide range of nonspecific symptoms, and nephropexy was performed much more frequently than it is today. Recognition that many mobile kidneys were harmless, together with inconsistent surgical results, led to scepticism and a marked decline in treatment.[1]

Modern positional imaging and minimally invasive surgery have renewed interest. However, the evidence remains dominated by small observational series and case reports rather than robust randomised comparisons. There is also no universally accepted combination of symptoms and test findings that predicts success for an individual.[2,6,8]

The appropriate response is to take the symptoms seriously while investigating the cause carefully. A normal routine scan does not mean pain is imagined. A mobile kidney does not mean an operation will solve it.

When should you seek urgent care?

Severe or escalating flank pain, fever or rigors, persistent vomiting, visible blood in the urine, or a marked reduction in urine output warrant prompt medical assessment. These symptoms can signal infection, obstruction or another problem requiring urgent treatment, regardless of whether nephroptosis is present.

This article provides general education. Diagnosis and treatment require an individual clinical assessment.

Patient information by Dr Jo Schoeman | Evidence reviewed October 2026

References

  1. Moss SW. Floating kidneys: a century of nephroptosis and nephropexy. Journal of Urology. 1997;158(3 Pt 1):699–702. doi:10.1016/S0022-5347(01)64296-4.
  2. Barber NJ, Thompson PM. Nephroptosis and nephropexy—hung up on the past? European Urology. 2004;46(4):428–433. doi:10.1016/j.eururo.2004.03.023.
  3. Mogorovich A, Selli C, De Maria M, et al. Clinical reappraisal and state of the art of nephropexy. Urologia. 2018;85(4). doi:10.1177/0391560317749191.
  4. Senaratne R, Anderson S, Kelly C, et al. Rolling in the deep: an illustrative report of symptomatic nephroptosis. Radiology Case Reports. 2024;19(9):4044–4048. doi:10.1016/j.radcr.2024.06.047. Case report.
  5. Murari SB, Gadepalli T, Rao VP, Ram R. Renal scintigraphy in diagnosis and management of nephroptosis. Indian Journal of Nuclear Medicine. 2012;27(1):52–54. doi:10.4103/0972-3919.108874. Case report.
  6. Strohmeyer DM, Peschel R, Effert P, et al. Changes of renal blood flow in nephroptosis: assessment by color Doppler imaging, isotope renography and correlation with clinical outcome after laparoscopic nephropexy. European Urology. 2004;45:790–793. PubMed.
  7. Liu H, Gao W, Zhang Z, et al. Modified percutaneous nephropexy for nephroptosis: technical description and short-term results. Current Urology. 2025;19(3):168–172. doi:10.1097/CU9.0000000000000238. Small technical series; four patients.
  8. Plas E, Daha K, Riedl CR, Hübner WA, Pflüger H. Long-term followup after laparoscopic nephropexy for symptomatic nephroptosis. Journal of Urology. 2001;166(2):449–452. PubMed.

Ureteroceles: symptoms, investigations and treatment

/0 Comments/in , , /by

A ureterocoele (also spelt ureterocele) is a balloon-like swelling at the lower end of a ureter: the tube carrying urine from the kidney to the bladder. The swelling usually projects into the bladder. Its opening may be narrow, slowing urine drainage and sometimes causing infection, stones or pressure on the kidney.

Some ureterocoeles cause no problems and are found incidentally. Others need treatment to improve drainage and protect kidney function. [1,2]

Congenital or acquired?

Most true ureteroceles are congenital, meaning they develop before birth. They may be detected on pregnancy ultrasound, during childhood or much later in adult life. A diagnosis in adulthood does not necessarily mean the ureterocele developed recently.

A ureterocoele can occur with a single ureter or a duplex collecting system, in which a kidney has two drainage systems. In a duplex kidney, the ureterocoele commonly involves the ureter draining the upper part of the kidney.

An intravesical or orthotopic ureterocoele lies within the bladder. An ectopic ureterocoele extends into the bladder neck or urethra and may interfere with bladder emptying. Adults more often have an intravesical ureterocoele associated with a single drainage system. [1,3]

The term “acquired ureterocoele” needs care. An acquired swelling of the lower ureter that resembles a ureterocoele is often called a pseudoureterocoele. A stone or a lesion involving the bladder near the ureteric opening can cause this appearance. An irregular or unusual swelling should therefore be investigated rather than assumed to be a harmless congenital abnormality. [4]

Presentation and symptoms

A ureterocoele may be discovered during investigations for an unrelated problem. When symptoms occur, they can include:

  • Recurrent urinary tract infections.
  • Pain in the side, back or lower abdomen.
  • Burning, urgency or frequent urination, particularly with infection.
  • Blood in the urine.
  • Stones trapped within the ureterocoele.
  • Difficulty emptying the bladder or, occasionally, urinary retention.

Children may present with unexplained fever, feeding difficulties or poor growth associated with infection. Rarely, a large ureterocoele can prolapse through the urethra.

Symptoms depend on whether the swelling obstructs drainage, contains a stone or affects the bladder outlet. Prolonged obstruction and repeated kidney infections can damage kidney function. [2,5]

What investigations are needed?

Investigations establish the anatomy, assess drainage and kidney function, and look for infection or reflux. Not everyone needs every test.

Investigation What it helps assess
Urine testing and culture Infection and the appropriate antibiotic
Blood tests Kidney function; inflammatory markers when infection is suspected
Kidney and bladder ultrasound The ureterocoele, stones and swelling of the kidney or ureter
CT, sometimes CT urography Stones and detailed urinary tract anatomy, particularly in adults
MR urography Complex anatomy, including duplicated drainage systems
MAG3 or DMSA kidney scan Drainage and relative function, or functioning kidney tissue and scarring
Micturating cystourethrogram (MCUG/VCUG) Urine flowing backwards from the bladder into a ureter
Cystoscopy Direct inspection of the bladder and ureteric openings

CT involves radiation; contrast use depends on kidney function and the clinical question. Reflux testing is particularly relevant in children or when infection, complex anatomy or postoperative concerns warrant it. Cystoscopy can clarify an uncertain diagnosis and allow treatment during the same procedure. [1,3,5]

Does every ureterocoele need surgery?

No. Observation with planned follow-up may be appropriate when there are no troublesome symptoms, significant obstruction or recurrent infections, and kidney function is satisfactory.

Monitoring may include ultrasound and review of symptoms. Antibiotics treat infection but do not correct the swelling. Preventive antibiotics are considered selectively, particularly in children at increased infection risk. [6]

An infected, obstructed kidney requires urgent assessment and drainage, alongside antibiotics. Drainage may involve endoscopic opening of the ureterocoele or a nephrostomy, a tube placed through the skin into the kidney. Antibiotics alone may be insufficient when infected urine cannot drain. [1]

Endoscopic incision or deroofing

Treatment can often be performed through a telescope passed along the urethra into the bladder, usually under general anaesthesia.

Incision or puncture creates an opening in the wall of the ureterocoele. Deroofing removes part of its wall to create a broader opening. Both aim to let urine drain freely and reduce the balloon-like swelling.

The choice depends on anatomy, obstruction and associated stones. Instruments using electrical energy or a laser may be used. A stone within the sac can sometimes be fragmented and removed at the same operation.

A bladder catheter may be needed temporarily. Endoscopic treatment can be sufficient for a straightforward adult intravesical ureterocoele, while complex duplex or ectopic cases may need further surgery. [5,7,8]

Where does a ureteric stent fit in?

A double-J stent is a soft internal tube extending from the kidney to the bladder. It may be used selectively to support drainage after treatment, during associated stone surgery or while swelling settles. It is not required in every case and does not necessarily provide a permanent solution to the ureterocoele. [8]

Stents can cause frequency, urgency, bladder discomfort, blood in the urine and flank pain, sometimes after urination. Infection, displacement and mineral encrustation are other possible problems.

Every temporary stent needs a clear removal or exchange plan. The duration depends on the procedure and clinical circumstances. Contact the treating team if the removal date is unclear or overdue. [9]

Possible complications, including vesicoureteric reflux

Possible complications of endoscopic treatment include bleeding, infection, discomfort, injury to nearby urinary tract structures, persistent obstruction or narrowing as the opening heals. Repeat treatment or reconstructive surgery may be needed. [3,5,7]

Vesicoureteric reflux (VUR) means urine travels backwards from the bladder towards the kidney. It may already be present before treatment, particularly in a duplex system, or develop after opening the ureterocoele alters the natural anti-reflux mechanism.

Reflux does not automatically mean kidney damage or another operation. Its significance depends on its severity, infections, kidney function and bladder function. Monitoring may be appropriate; persistent significant reflux with recurrent infections can require further treatment, including ureteric reimplantation.

Risk varies with anatomy and technique. Ectopic ureterocoeles and duplex systems have higher rates of postoperative reflux and additional surgery than simpler intravesical cases. [1,7]

In one small adult study, reflux was detected in two of 23 patients followed after endoscopic incision, persisting in one at six months. These results illustrate the possibility of reflux; they do not predict an individual patient’s risk. Adult evidence largely comes from small studies. [7]

Further surgery and follow-up

Reconstructive options include reimplanting the ureter into the bladder or joining it to another healthy ureter in a duplex system. Occasionally, a severely damaged, poorly functioning kidney segment causing problems may require removal. Specialist assessment determines whether reconstruction, observation or removal is appropriate. [1]

Follow-up checks that drainage has improved and looks for recurrent infection, obstruction or reflux. Ultrasound is commonly used; further imaging is selected according to the findings. Symptom improvement alone does not confirm that drainage is normal. [5,7]

Seek urgent medical care for fever or shaking chills with flank pain, inability to pass urine, severe worsening pain, persistent vomiting or feeling seriously unwell. These symptoms may indicate infection or obstruction, including after treatment or with a stent in place. [1,9]

This article provides general education. Treatment should be tailored to the patient’s anatomy, symptoms and kidney function in consultation with their urologist.

References

  1. European Association of Urology. EAU Guidelines on Paediatric Urology: Ureterocele and ectopic ureter. Current online guideline, accessed 5 October 2026. https://uroweb.org/guidelines/paediatric-urology/chapter/ureterocele-and-ectopic-ureter
  2. European Association of Urology. Patient information: Ureterocele. https://patients.uroweb.org/condition/duplex-congenital-malformations-of-the-urinary-tract/ureterocele
  3. The Outcome of Transurethral Electro-Endoscopic Resection of Orthotopic Single System Ureterocoeles in Adults Nigerians. https://pmc.ncbi.nlm.nih.gov/articles/PMC11073836/
  4. Thornbury JR, Silver TM, Vinson RK. Ureteroceles vs. pseudoureteroceles in adults. Urographic diagnosis. Radiology. 1977;122(1):81–84. doi:10.1148/122.1.81. https://pubmed.ncbi.nlm.nih.gov/830358/
  5. An adult ureterocele complicated by a large stone: A case report. International Journal of Surgery Case Reports. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5927814/
  6. European Association of Urology. Watchful waiting for ureterocele. https://patients.uroweb.org/condition/duplex-congenital-malformations-of-the-urinary-tract/ureterocele/wait-and-see-ureterocele
  7. Vijay MK, et al. The safety and efficacy of endoscopic incision of orthotopic ureterocele in adult. Saudi Journal of Kidney Diseases and Transplantation. 2011;22(6):1169–1174. https://pubmed.ncbi.nlm.nih.gov/22089776/
  8. A Large Stone Within a Ureteroceles: A Diagnostic Pitfall and the Utility of Holmium Laser Deroofing as a Viable Surgical Option. https://pubmed.ncbi.nlm.nih.gov/29468199/
  9. British Association of Urological Surgeons. Information about your ureteric stent. https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/Stent%20advice.pdf

Vaginal vault prolapse: understanding the options

/0 Comments/in , , , , /by

Patient information | Reviewed 28 September 2026

Vaginal vault prolapse occurs when the top of the vagina descends after a hysterectomy. It can occur alone or alongside a bulge of the front vaginal wall (anterior prolapse, often called a cystocele). Some women feel a bulge, dragging or pressure; others have difficulty emptying their bladder, recurrent urinary infections, bowel symptoms or discomfort during sex. The size of a prolapse on examination does not always match how troublesome it feels. Treatment should be guided by symptoms and personal priorities, rather than the examination alone. [1,2]

Why the front wall matters

The vaginal apex helps support the front and back walls. An anterior bulge may partly reflect loss of support at the apex. Repairing only the front wall while leaving significant vault prolapse untreated may leave the underlying problem unresolved. Conversely, restoring apical support may improve some anterior prolapse, although a separate anterior repair is sometimes needed. The surgeon should assess each compartment before deciding which parts require treatment. [1,3]

Assessment and treatment without surgery

Assessment includes a history of bulge, urinary and bowel symptoms, sexual function, prior hysterectomy and prolapse operations; examination while straining; and discussion of what the woman wants treatment to achieve. A bladder scan for residual urine is useful when emptying is difficult. Urine tests, urodynamics or imaging are considered for specific questions rather than required for every woman. Stress leakage can be hidden by a large prolapse and may appear after it is reduced or repaired; this possibility deserves discussion before surgery. [1,2]

If symptoms are mild, observation is reasonable. Pelvic floor muscle training can improve symptoms, particularly with less advanced prolapse, but cannot reliably lift a substantial vault prolapse back into place. A vaginal pessary can relieve a bulge without surgery and can also help someone decide whether restoring support improves bladder or bowel symptoms. Pessaries require fitting and ongoing review. Vaginal oestrogen may help postmenopausal vaginal dryness or irritation when appropriate; it is not a cure for the prolapse. [1,2]

Surgical options

Approach How the apex is supported Main considerations
Vaginal sacrospinous fixation Stitches attach the vaginal top to a pelvic ligament, usually on one side. Avoids an abdominal incision and implanted mesh; possible temporary buttock pain and recurrent anterior bulge.
Vaginal uterosacral ligament suspension Stitches attach the vaginal top to the uterosacral ligaments. Uses the woman’s own tissues; attention to the ureters is essential, often with cystoscopy during surgery.
Sacrocolpopexy (laparoscopic, robotic or open) Mesh attached to the vagina is fixed to the ligament over the sacrum through the abdomen. Often durable apical support; abdominal operative risks and mesh-specific risks must be weighed.
Colpocleisis The vaginal canal is closed or substantially shortened. Effective option for selected women who do not wish to retain vaginal intercourse; the loss of vaginal intercourse is permanent.

An anterior repair may be added if the front wall remains significantly prolapsed after apical support is restored. These operations can also be combined with treatment of stress incontinence when the benefits and added risks justify it. The decision is individual. [1–3]

Where does robotic sacrocolpopexy fit?

Robotic sacrocolpopexy is one way to perform abdominal sacrocolpopexy through small incisions. The robot helps the surgeon control instruments; it does not perform the surgery independently. It may be considered for symptomatic, substantial or recurrent vault prolapse, especially when preserving vaginal length and durable apical support are priorities, or when multiple compartments need reconstruction. It is not necessary for every prolapse and is not suitable for every patient. Previous abdominal operations, anaesthetic risk, ability to tolerate the operating position, mesh preferences, surgeon experience and costs all matter. [1–4]

Compared with vaginal operations using the patient’s own tissue, sacrocolpopexy generally has lower rates of recurrent prolapse and repeat prolapse surgery in studies of post-hysterectomy vault prolapse. In the 2023 Cochrane review, illustrative estimates were 6 in 100 requiring repeat surgery after sacrocolpopexy versus 14 in 100 after vaginal procedures, and 8 in 100 noticing recurrent prolapse versus 18 in 100 after vaginal procedures. These are pooled comparisons, not predictions for an individual. The certainty and length of follow-up vary. [3]

A multicentre randomised trial reported a 36-month composite treatment-failure estimate of 28% with sacrocolpopexy and 43% with vaginal native-tissue repair. Its definition combined symptoms, examination findings and retreatment: it does not mean 28% underwent another operation. Women in all groups reported sustained improvement, with similar satisfaction and decision regret. [4]

The benefit shown for sacrocolpopexy should not be attributed specifically to the robot. Comparative studies have not established better long-term anatomical or patient-reported results for robotic versus conventional laparoscopic sacrocolpopexy. Operating time and cost can be higher with robotic surgery, depending on the centre and surgeon. The quality of the repair and the experience of the team may matter more than the instrument platform. [5,6]

Risks and complications

Every prolapse operation can involve bleeding, infection, clots, anaesthetic complications, injury to the bladder, bowel or ureters, temporary difficulty emptying the bladder, new or persistent urinary leakage or urgency, constipation, pain with intercourse, and recurrence. A bulge can return in a different compartment even when the apex remains well supported. Some women need further treatment. Individual risk varies with previous operations and health. [1–4]

Sacrocolpopexy adds risks associated with abdominal access and permanent mesh, including mesh exposure through the vagina, infection, pain, and rarely erosion into an organ or complications near the sacrum. Mesh complications can arise years later and sometimes require further surgery. The 2024 randomised trial reported mesh exposure in about 3% after sacrocolpopexy during its follow-up; this is a study figure, not a lifetime risk. Vaginal native-tissue surgery avoids implanted mesh but has its own risks, including buttock pain with sacrospinous fixation and ureteric obstruction or injury with uterosacral suspension. [1,3,4]

An Australian distinction: Mesh inserted through the vagina to repair prolapse is not available for routine supply in Australia. That is different from mesh inserted through the abdomen for sacrocolpopexy, which remains an available category of device. An operation should never be described simply as “mesh-free” or “mesh surgery” without explaining the route, material and specific risks. [7]

Making a decision

There is no single best operation for every woman. A useful consultation covers how bothersome the bulge is; whether a pessary has been tried; the degree of vault and anterior prolapse; bladder, bowel and sexual symptoms; previous repairs; the wish to avoid mesh; the wish to maintain vaginal intercourse; likely recovery; and the surgeon’s experience with each approach. It should distinguish improvement in symptoms from an examination-based definition of anatomical success. For women seeking a durable reconstruction, sacrocolpopexy is an important option; vaginal native-tissue surgery remains a valid choice, particularly when avoiding abdominal surgery or mesh matters more. [1–4]

This article provides general information and cannot replace an individual examination and discussion of personal risks and goals.

References

  1. NICE. Urinary incontinence and pelvic organ prolapse in women: management (NG123). 2019, subsequent updates.
  2. RCOG. Pelvic organ prolapse: patient information.
  3. Maher C, et al. Surgery for women with apical vaginal prolapse. Cochrane Database Syst Rev. 2023;7:CD012376. doi:10.1002/14651858.CD012376.pub2.
  4. Menefee SA, et al. Apical suspension repair for vaginal vault prolapse: a randomized clinical trial. JAMA Surg. 2024.
  5. Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial. Obstet Gynecol. 2014.
  6. Ferrari A, et al. Laparoscopic versus robot-assisted sacrocolpopexy: systematic review and meta-analysis. 2026.
  7. Therapeutic Goods Administration. About transvaginal surgical mesh devices.

Small renal masses: observation, surgery and image-guided ablation

/0 Comments/in , /by

An unexpected spot on a kidney scan can be alarming. A small renal mass usually means a solid, enhancing growth measuring 4 cm or less and confined to the kidney. It is not automatically cancer: some are benign, and many small kidney cancers grow slowly. The right approach depends on the scan, any biopsy result, kidney function, other health conditions and what matters to you. [1,2]

How do we investigate it?

I review the original imaging and usually arrange a dedicated, multiphase contrast CT or MRI to establish whether the lesion enhances, its size and position, and whether it looks like a simple cyst or another benign condition. Blood tests assess kidney function. The need for chest imaging depends on the findings and clinical circumstances. If contrast is unsuitable because of impaired kidney function, we plan an alternative with the radiologist. [1,2]

A needle biopsy can help when knowing whether a mass is benign or what type of cancer it contains would change the decision. A biopsy can occasionally be inconclusive. If ablation is planned, the European Association of Urology (EAU) recommends biopsy before a separate ablation session to avoid treating benign lesions unnecessarily. [1]

What are the choices?

Approach When it may suit Main consideration
Active surveillance A very small mass, particularly under 2 cm; slow growth; or a patient who prefers to defer treatment Planned scans and a clear trigger to reconsider treatment
Partial nephrectomy A mass requiring treatment when kidney-sparing surgery is technically suitable Removes the tumour and supplies a complete specimen, but requires an operation
Percutaneous ablation A selected small mass when treatment is indicated, especially if surgery carries greater risk or preserving kidney tissue is important Less invasive, but imaging follow-up is essential and repeat treatment may be needed
Radical nephrectomy A tumour that cannot reasonably be treated with a kidney-sparing approach Removes the whole kidney and may have a greater effect on kidney function

For masses under 2 cm, surveillance is often a sensible first option. For masses 2–4 cm, surveillance, partial nephrectomy and ablation may all deserve discussion. If surgery is appropriate, guidelines generally favour partial nephrectomy for a treatable small cancer. Frailty or limited life expectancy may make symptom-focused observation preferable. [1,2]

Surveillance is an active plan, not neglect. Scans are often repeated every 3–6 months initially and then every 6–12 months if stable, with timing adapted to the individual. Growth beyond 4 cm, repeated growth above approximately 5 mm a year, new concerning features or patient preference can prompt reconsideration; growth rate alone does not prove that a mass is dangerous. [2]

What is radiofrequency ablation (RFA)?

RFA destroys tissue by passing an electrical current through a thin probe, generating heat inside the mass. An interventional radiologist usually places the probe through the skin using CT or ultrasound guidance. Anaesthesia or sedation, patient positioning and sometimes fluid injected to protect nearby bowel are planned around the tumour’s location. The radiologist treats the mass and a small surrounding margin, then checks for immediate complications. Many patients have a short hospital stay, but arrangements vary. [1–3]

RFA is most established for small, accessible masses, particularly those up to 3 cm. A mass deep in the kidney, next to the urine-drainage system or bowel, or near major vessels can be harder to treat safely or completely. EAU guidance advises against routinely offering RFA for masses over 3 cm, because control becomes less reliable. A mass between 3 and 4 cm needs an individual discussion rather than an automatic exclusion. [1]

What other ablation methods are available?

  • Cryoablation uses probes to freeze the tumour. The visible ice ball can help the operator plan the treatment margin. It is an established alternative to RFA; the EAU advises against its routine use for tumours over 4 cm. [1,2]
  • Microwave ablation uses microwave energy to heat tissue. Experience is growing and the EAU describes encouraging results, though long-term comparative evidence remains less certain than for surgery. Availability and expertise vary. [1]
  • Irreversible electroporation delivers electrical pulses to disrupt cell membranes. Evidence for routine treatment of small renal cancers remains limited. [2]
  • Stereotactic ablative radiotherapy (SABR/SBRT) directs highly focused radiation without inserting a probe. It can be discussed for selected patients who need treatment but are unsuitable for surgery; long-term comparisons remain limited. [1]

The choice depends on tumour size and position, prior treatment, kidney function, local expertise and the patient’s preferences. No technique is right for every lesion.

Benefits, limitations and risks

Percutaneous ablation can avoid a surgical incision, usually involves less immediate recovery than surgery and can preserve functioning kidney tissue. Risks include bleeding, infection, pain, injury to the urine-collecting system or nearby organs, and incomplete treatment or local recurrence. Risks depend strongly on where the tumour sits. A second ablation or surgery may be possible if follow-up imaging shows persistent disease. [1,2]

Evidence comparing ablation with partial nephrectomy largely comes from observational studies involving patients with different health risks. Ablation offers good local control for carefully selected small tumours, but its long-term cancer control relative to surgery is less certain; it should not be described as a guaranteed equivalent. [1,2]

What happens after ablation?

Treatment destroys the lesion in place, so there is no whole-tumour surgical specimen. Contrast-enhanced CT or MRI checks for remaining enhancing tissue and later recurrence. One published guideline suggests imaging at 3, 6 and 12 months, then annually after ablation, adjusted to biopsy findings, renal function and the treating team’s protocol. We also monitor kidney function. A new enhancing focus requires specialist review and may lead to repeat biopsy or treatment. [1,2]

My role in your care

I can review the findings and discuss surveillance, biopsy and the treatment choices with you. I no longer perform nephrectomies. If an operation is the best option, I will refer you to a colleague who performs kidney surgery. If ablation appears suitable, I will arrange assessment by an experienced interventional radiology team; the final decision follows review of the images and your overall health.

Seek urgent medical attention for heavy visible bleeding, inability to pass urine, fever with flank pain, or severe worsening pain after a procedure.

This article provides general information. Individual advice requires assessment of your imaging, biopsy findings where relevant, kidney function and medical history.

Dr Jo Schoeman | Patient information | September 2026

References

  1. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Disease Management, current online edition, accessed September 2026.
  2. Richard PO, et al. Canadian Urological Association guideline: Management of small renal masses. Canadian Urological Association Journal. 2022;16(2)–E75.
  3. Park BK, et al. Asian Conference on Tumor Ablation guidelines for renal cell carcinoma. Investigative and Clinical Urology. 2021.
  4. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Follow-up, current online edition, accessed September 2026.

A kidney tumour larger than 3 cm: what does it mean?

/0 Comments/in , /by

By Dr Jo Schoeman | Patient information | September 2026

Finding a kidney mass can be frightening. The first question is whether it is cancer; the next is whether it is confined to the kidney. A mass measuring 3.1 cm is not automatically advanced cancer. If a renal cell carcinoma (RCC) is no more than 4 cm and remains within the kidney, it is classified as T1a. A tumour over 4 cm but no more than 7 cm, still confined to the kidney, is T1b. Lymph-node and distant spread are assessed separately. Some kidney masses are benign, and imaging alone cannot always tell us which. [1–3]

How might it present?

Many tumours are discovered by chance during an ultrasound or CT scan for another problem. Others cause blood in the urine, persistent pain in the side or back, or occasionally a palpable lump. Unexplained weight loss, fatigue, anaemia or fever warrant assessment, although they have many possible causes. The combination of blood in the urine, pain and a palpable mass is uncommon. Visible blood in the urine should always be investigated; a kidney mass does not rule out another source of bleeding. [2]

What investigations are needed?

  • Dedicated imaging: A multiphase contrast CT of the kidneys and abdomen shows whether the lesion enhances, its exact position, its relationship to major blood vessels and the collecting system, and whether there are enlarged nodes or signs of spread. Chest imaging completes staging; its extent is tailored to the tumour and clinical circumstances. MRI may clarify an uncertain lesion or suspected tumour extension into a vein, or be useful when CT contrast is unsuitable. A complex kidney cyst needs its own imaging assessment. [2]
  • Blood and urine tests: Kidney function (creatinine and eGFR), a full blood count and other tests guided by the clinical picture help assess fitness for treatment and preserve kidney function. Urine testing may identify infection or another cause of bleeding. [2]
  • Biopsy: A needle biopsy can be useful if its result will change management, particularly before ablation or drug treatment without prior tissue diagnosis. A typical surgically removable solid mass does not always need a biopsy beforehand. A biopsy can occasionally be inconclusive. [2]
  • Further staging: Bone or brain scans are generally reserved for relevant symptoms or suspected advanced disease. Routine PET scans and bone scans are not recommended for initial RCC staging. [2]

The team should review the images, kidney function, other medical conditions and the patient’s priorities together. An indeterminate mass should not be labelled definitively as RCC before appropriate assessment.

A note about my practice: I no longer perform nephrectomies. I can assess your kidney mass, discuss the findings and treatment options with you, and, if an operation is appropriate, refer you to a colleague who performs kidney surgery. We can also arrange input from a multidisciplinary team where needed.

Treatment when the tumour is confined to the kidney

Partial nephrectomy removes the tumour while preserving the rest of the kidney. This is generally preferred for T1 cancers when technically feasible, particularly if kidney function is reduced or there is only one functioning kidney. It can be performed by robotic, laparoscopic or open surgery according to tumour complexity and surgical expertise. Risks include bleeding, urine leak, infection, reduced kidney function and, occasionally, the need to remove the whole kidney. [1]

Radical nephrectomy removes the kidney and may be appropriate when a safe partial nephrectomy is not feasible, particularly with a larger or more complex tumour. Robotic or laparoscopic surgery offers an approach to the operation; it does not change the underlying choice between partial and radical removal. [1]

Active surveillance may suit selected people with a small, slow-growing mass, competing health risks or a strong preference to defer treatment. It involves planned scans and a clear trigger to reconsider treatment. A tumour just above 3 cm needs a particularly careful discussion because the room for further growth before 4 cm is limited. Thermal ablation, such as cryoablation or radiofrequency or microwave ablation, may suit selected small tumours, especially when surgery is unsuitable; a biopsy is recommended before ablation. Local recurrence and the possible need for repeat treatment should be discussed. [1, 2]

Stereotactic ablative radiotherapy (SABR) is also being used in specialist centres for selected patients with localised RCC who cannot undergo surgery. It is a distinct option from routine radiation after an operation, and its long-term comparative evidence continues to mature. [1]

What if lymph nodes look enlarged?

An enlarged node on a scan is suspicious, not proof of cancer; inflammation can also enlarge nodes. The team considers the appearance and site of the nodes, whether there is disease elsewhere and whether tissue confirmation will change treatment. If nephrectomy is planned, visibly enlarged regional nodes may be removed for diagnosis and staging. Removing normal-looking nodes routinely has not been shown to improve survival for organ-confined RCC. The survival benefit of removing involved nodes is uncertain. [1]

Confirmed regional node involvement is a substantial change in risk even if the kidney tumour is small. It calls for multidisciplinary discussion about whether all visible disease can be removed, whether postoperative drug treatment is appropriate, and how closely to monitor. Nodes beyond the regional area, or spread to organs such as the lung or bone, may represent metastatic disease and require a different plan. Surgery on the kidney is not automatically the best first step when cancer is widespread. [1, 3]

When does immunotherapy help?

For selected patients with clear-cell RCC at higher risk of recurrence after complete surgery, a course of pembrolizumab may lower recurrence risk and has shown an overall survival benefit in the KEYNOTE-564 study. The eligible groups include some patients with confirmed regional node involvement and no distant metastases. A 3–4 cm node-negative tumour confined to the kidney would not usually qualify based on size alone. The final pathology, stage and overall health matter. [1, 4]

If cancer has spread and cannot all be removed, initial treatment for clear-cell RCC often combines immune checkpoint drugs with each other (nivolumab plus ipilimumab) or combines immunotherapy with an oral targeted drug (for example, pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or nivolumab plus cabozantinib). The best regimen depends on risk group, other illnesses, kidney function, previous treatment and the specific cancer subtype. Papillary and other non-clear-cell cancers may need different approaches. Availability and subsidy in Australia should be checked for the individual indication. [1]

Immunotherapy can cause serious inflammation of the bowel, lungs, liver, kidneys or hormone-producing glands; targeted drugs can cause high blood pressure, diarrhoea, fatigue and other adverse effects. Some immune effects can persist after treatment ends. Benefits and risks need an individual discussion with a medical oncologist. [1, 4]

Is chemotherapy useful?

Conventional cytotoxic chemotherapy is generally ineffective for the common types of RCC and is not standard treatment for ordinary clear-cell RCC. Rare subtypes, including collecting duct and renal medullary carcinoma, are exceptions in which chemotherapy may have a role. A cancer arising from the lining of the renal pelvis (upper-tract urothelial carcinoma) is a different disease with different chemotherapy options; establishing the diagnosis matters. [1]

Does radiation offer a benefit?

Radiotherapy is not routinely given after nephrectomy to prevent recurrence of localised RCC. Its clearest established role is treating specific problems from spread, such as painful bone lesions, brain metastases or symptoms from another site. Precisely targeted radiation may also control selected limited metastases or treat a primary tumour in someone unsuitable for surgery. Whether it adds benefit to systemic therapy or surgery in an individual case depends on the site, number and behaviour of lesions and is best decided with radiation oncology input. It should not be presented as a standard substitute for an operable partial nephrectomy. [1, 5]

Questions worth asking at your consultation

  1. Is this definitely a solid enhancing kidney tumour, and what is its exact size and location?
  2. Is the disease confined to the kidney? Are any nodes merely enlarged, or proven to contain cancer?
  3. Can we safely preserve part of the kidney? What is my current kidney function?
  4. Would a biopsy change the plan?
  5. If the cancer is clear-cell and higher risk, would adjuvant pembrolizumab be suitable?
  6. Would drug treatment or targeted radiation offer a benefit in my particular situation?

Seek prompt medical attention for heavy bleeding with clots, inability to pass urine, severe persistent pain, or sudden neurological symptoms. This article is general information and cannot replace review of your scans and pathology at a multidisciplinary meeting.

References

  1. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Disease Management. 2026.
  2. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Diagnostic Evaluation. 2026.
  3. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Staging and Classification Systems. 2026.
  4. National Cancer Institute. Adjuvant Keytruda improves kidney cancer survival, reporting updated KEYNOTE-564 outcomes. 2024.
  5. National Cancer Institute. Renal Cell Cancer Treatment (PDQ), Health Professional Version. Accessed September 2026.

Coffee Break

/0 Comments/in /by

Coffee, oat milk and the start of my day at the Wesley

By Dr Jo Schoeman

Before a busy day of consultations or operating at the Wesley, I enjoy a small ritual: stopping for a coffee with oat milk at Steamtrain Espresso Bar and Kitchen, beside Auchenflower train station and just outside the hospital. It gives me a moment to gather my thoughts before the day begins. I also simply enjoy a good coffee.

 “A quiet coffee before the working day.” 

What is good about coffee?

For many of us, caffeine helps us feel more alert and focused in the morning. Coffee also contains a range of naturally occurring plant compounds. Large reviews have found that people who drink moderate amounts of coffee tend to have lower rates of several health problems than people who do not drink it. These are mostly associations: they do not prove that coffee itself prevents disease, and they are no reason to start drinking it if you do not enjoy it.[1]

The amount that suits one person may be too much for another. Coffee can disturb sleep or cause jitters and palpitations, especially in people who are sensitive to caffeine. I prefer mine early in the day, when I can enjoy the lift without letting it interfere with the night ahead.

Why oat milk?

I like its taste and the creamy texture it brings to coffee. It is a practical dairy-free option for people who avoid cow’s milk. If oat milk is a regular replacement for dairy, however, it pays to check the carton: products vary, and oat milk usually provides less protein than cow’s milk. Choosing an unsweetened product fortified with calcium can help, while vitamin B12 and iodine are also worth considering in the context of your overall diet.[2,3] A splash in a coffee is a pleasure, rather than a nutritional strategy in itself.

A urologist’s small caveat

I cannot write about coffee without mentioning the bladder. Caffeine can make urinary urgency, frequency or night-time trips to the toilet worse for some people. If that sounds familiar, try a smaller coffee, have it earlier, or see whether decaf makes a difference. Keep drinking an appropriate amount of water; cutting fluids too far can make bladder symptoms worse. Persistent symptoms deserve an assessment rather than being blamed on your morning coffee alone.[4]

For me, that oat milk coffee at Steamtrain marks the start of the working day. It is a pleasant pause, a familiar stop by the station, and a chance to arrive at the Wesley ready to see my patients. Like most good habits, it works best with a little balance.

References and further reading

  1. Poole R, et al. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359. https://www.bmj.com/content/359/bmj.j5024
  2. Dietitians Australia. Plant-based milks. https://dietitiansaustralia.org.au/health-advice/plant-based-milks
  3. Food Standards Australia New Zealand. Plant-based milk alternatives. https://www.foodstandards.gov.au/consumer/nutrition/milkaltern
  4. Continence Health Australia. Caring for your bladder at night (nocturia). https://www.continence.org.au/about-incontinence/urinary-incontinence/nocturia/caring-for-your-bladder-at-night-nocturia/

This article offers general information and reflects my personal routine. Individual nutrition and bladder needs vary.

Prostate cancer with kidney failure: is surgery, focal therapy or radiation the right choice?

/0 Comments/in , /by

A patient guide by Dr Jo Schoeman

A diagnosis of prostate cancer is unsettling. Having chronic kidney disease or needing dialysis can make treatment decisions feel even harder. The reassuring point is that kidney failure does not automatically rule out treatment. The best choice depends on the cancer, the degree of kidney impairment, other medical conditions and, crucially, whether a kidney transplant is planned.

What does Gleason 3+4 mean?

Gleason 3+4=7 is Grade Group 2 prostate cancer. Most of the sampled tumour has pattern 3, with a smaller component of pattern 4. It is generally less concerning than Gleason 4+3=7, but “3+4” alone cannot tell us whether immediate treatment is needed.

I would review the PSA and PSA density, examination, MRI findings, number and length of positive biopsy cores, percentage of pattern 4, any cribriform or intraductal cancer, and whether disease is confined to the prostate. Kidney function, dialysis schedule, life expectancy and transplant eligibility are considered alongside these findings. Some men have favourable intermediate-risk cancer; others have features that make definitive treatment more appropriate. Staging scans are selected according to overall risk rather than biopsy grade alone. [1,2]

Could active surveillance be reasonable?

Yes, for selected men with small-volume, favourable Grade Group 2 cancer. Surveillance means scheduled PSA tests, clinical review, MRI where useful and repeat biopsy when indicated. It keeps treatment available if the cancer changes. It is a particularly meaningful option when another serious illness makes the harms of immediate treatment more likely to outweigh its benefit. It does, however, require a patient who can attend follow-up and accepts a small increased risk of progression compared with immediate treatment. [1,2]

If kidney disease or other illnesses substantially limit life expectancy, watchful waiting may be more appropriate: care focuses on symptoms rather than routine testing intended to trigger curative treatment. This is a separate decision from active surveillance. [1]

Can radical prostatectomy or robotic surgery be performed?

Often, yes. Chronic kidney disease and dialysis are not automatic contraindications to radical prostatectomy. Robotic assisted surgery may offer less blood loss and a shorter hospital stay than open surgery in selected patients, but it still involves general anaesthesia, abdominal insufflation and a head-down operating position. Advanced kidney disease increases the importance of planning for bleeding, infection, fluid and electrolyte balance, medication dosing and postoperative kidney injury. Population studies find higher complication rates in patients with chronic kidney disease, particularly advanced disease; individual risk varies considerably. [3,4]

Before an operation I would coordinate with the nephrologist, anaesthetist and, where relevant, dialysis team. We would assess cardiovascular health, haemoglobin, potassium, anticoagulants, residual kidney function and the timing of dialysis. Surgery also carries the usual risks of urinary leakage or incontinence, erectile dysfunction, infertility, blood clots and possible need for further cancer treatment. Whether a robotic approach is feasible depends on the patient and the surgical team; it is not automatically a safer choice for every person with kidney failure. [1,3,4]

Is focal therapy a better option?

Not simply because the kidneys are failing. Focal therapy treats the visible cancer-bearing portion of the prostate, using a technique such as focused ultrasound, cryotherapy or another ablative method. It may appeal to men hoping to reduce urinary or sexual side effects, but the cancer can be present elsewhere in the gland, and longer-term cancer control is less certain than for established whole-gland treatments. Further MRI, biopsies and sometimes repeat treatment are necessary.

The AUA/ASTRO guideline notes a lack of high-quality comparisons with surgery, radiation and surveillance. European guidance restricts focal treatment to settings with careful prospective follow-up, such as a trial or registry. Kidney disease alone does not establish that focal treatment is preferable. In a suitable patient it can be discussed with a specialist who explains uncertainty, access, costs and a clear follow-up plan. [1,2]

Is radiotherapy an option?

Yes. External beam radiotherapy avoids major surgery and usually does not expose the kidneys directly when treating a prostate confined to the pelvis. Options include moderately shortened courses and, for selected men, more condensed schedules or brachytherapy. The radiation oncologist will tailor treatment to the cancer and urinary function. Depending on whether the disease is favourable or unfavourable intermediate risk, a course of androgen deprivation therapy (ADT) may also be advised; ADT has its own effects on energy, muscle, bone and metabolic health. [1,2]

Radiotherapy may cause temporary urinary frequency, burning or bowel upset; longer-term urinary, bowel or erectile effects are also possible. Existing urinary obstruction and kidney transplant anatomy can change planning. In a transplant recipient, the graft and ureter may sit in the pelvis, so radiation dose constraints require particular attention. Dialysis, by itself, does not make prostate radiation impossible. [1,2]

What if a kidney transplant is planned?

This is a central part of the discussion. A transplant team may need to know whether the cancer is under surveillance or has been treated, its estimated risk of progression and the proposed follow-up. The presence of prostate cancer does not automatically mean that transplantation must wait for a fixed number of years; transplant eligibility is individual and should be discussed directly with the transplant team. A transplanted kidney in the pelvis also affects the planning of later pelvic surgery or radiotherapy. [5]

How do we decide?

Option When it may fit Main trade-off
Active surveillance Low-volume, favourable Grade Group 2 disease Regular testing and a possibility of later treatment
Robotic radical prostatectomy Fit patient seeking definitive local treatment Anaesthetic and surgical risks, with continence and erectile side effects
Radiotherapy Patient seeking definitive treatment without prostate removal Urinary, bowel and sexual effects; ADT may be needed
Focal therapy Carefully selected patient after discussion of uncertainty Less established long-term cancer control and ongoing biopsies
Watchful waiting Limited life expectancy or major competing health risks Treats symptoms if they arise rather than aiming for cure

There is no universal winner between robotic surgery and radiation for Gleason 3+4 cancer with kidney failure. A multidisciplinary discussion involving urology, radiation oncology, nephrology and the transplant team, if applicable, helps align cancer control with kidney health and the patient’s priorities.

This article offers general information and cannot determine treatment for an individual patient. Decisions require review of the pathology, imaging, kidney function and overall health.

References

  1. European Association of Urology. EAU Guidelines on Prostate Cancer: Treatment. Accessed September 2026.
  2. American Urological Association and American Society for Radiation Oncology. Clinically Localized Prostate Cancer Guideline. 2022.
  3. Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample. 2019.
  4. The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy. 2025.
  5. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. 2020.

Urethral bulking for stress urinary incontinence: a first procedure or an option after a sling?

/0 Comments/in , , /by

Leaking urine when you cough, laugh, exercise or lift something is called stress urinary incontinence (SUI). It differs from urgency incontinence, when a sudden need to pass urine leads to leakage. Some women have both. Identifying which symptom is most troublesome matters because an injection aimed at SUI will not reliably treat urgency.

Urethral bulking involves placing small deposits of material into the wall of the urethra, usually through a fine instrument passed into the urethra. The deposits help the urethra close when pressure rises. You may hear this described as periurethral bulking, although many contemporary injections are delivered through the urethra into its surrounding wall. This is generally a day procedure under local anaesthesia or sedation/general anaesthesia, depending on the circumstances. It does not place a sling or mesh tape.

Could bulking be my first procedure?

Yes. After a trial of pelvic floor muscle training and discussion of other conservative measures, bulking can be chosen as a first procedure for appropriately assessed SUI. It may appeal to someone seeking a shorter procedure and recovery, or wishing to avoid a sling. It is also an option when a larger operation or anaesthetic carries additional risk. It is not usually the first treatment before conservative care. USANZ’s 2026 position statement lists bulking alongside autologous fascial slings, colposuspension and synthetic midurethral slings among the standard options that should be discussed. UGSA’s patient information stresses its lower success and frequent need for repeat treatment. [1–3]

Bulking, synthetic midurethral sling surgery, a sling made from the patient’s own fascia, and colposuspension have different benefits and risks. A donated-tissue (allograft) sling is distinct from a sling made from your own tissue (autograft) and from a synthetic mesh sling; the strength and duration of evidence for each are different. No single procedure is best for every woman. [1,4]

How effective and durable is it?

The realistic aim is often less leakage, rather than guaranteed dryness. Success figures change substantially depending on whether researchers count complete dryness, improvement, satisfaction, or avoidance of further treatment. UGSA’s patient leaflet quotes about 40–50% cure or improvement and reports that approximately 30% need a further injection within two years. These are broad counselling figures, not a prediction for an individual. [2]

Some women remain improved for years, but repeat injections or another operation may be needed. In a randomised comparison of polyacrylamide hydrogel injection and synthetic tension-free vaginal tape for primary SUI, the tape achieved better objective continence at one year (negative cough test 95.0% versus 66.4%). The five-year follow-up did not establish that injection was non-inferior to tape. The EAU similarly advises that bulking is generally less effective than slings or colposuspension for cure, and that repeat injection is likely. These findings do not mean everyone should have a tape: the value of a less invasive procedure and the acceptability of a possible repeat treatment are personal considerations. [4–6]

What if I still leak after a sling?

Bulking can be considered for persistent leakage soon after a sling or recurrent leakage after an initial period of improvement. It can sometimes reduce leakage without placing another sling. A 2022 systematic review of 11 studies after synthetic midurethral sling failure reported a pooled 75% cure-or-improvement rate, but also pooled failure and further-operation rates of 32% and 25%. The studies differed considerably in their patients, products, follow-up and definitions of success; the 75% figure should not be presented as a personal chance of cure. An American Urogynecologic Society clinical practice statement also recognises bulking as an option after a sling. [7,8]

After an allograft sling, the same clinical possibility exists, but the published post-sling bulking evidence is mainly about synthetic midurethral slings. We should not simply transfer those success figures to donated-tissue slings. The precise graft, previous surgery and examination findings should guide an individual discussion.

An injection should not be used to mask a sling complication. Before offering more treatment, I would review the original operation, check urine and bladder emptying, examine for prolapse, scarring and vaginal exposure, and assess whether leakage occurs with coughing or with urgency. Cystoscopy, a bladder diary, pad testing or urodynamics may be appropriate, especially after previous surgery, mixed symptoms, pain, blood in the urine or difficulty emptying. A tape or graft causing obstruction, exposure, erosion, infection or pain may require its own assessment and treatment. [1,3,7]

Is it safe? What are the side effects?

Most reported problems are short lived, but no injection is risk free. Possible effects include:

  • burning when passing urine and a little blood in the urine;
  • urinary tract infection;
  • temporary difficulty emptying the bladder, occasionally requiring short-term catheterisation;
  • new or persisting urgency symptoms; and
  • incomplete benefit, recurrence or the need for another injection or operation.

Less commonly, there may be persistent pain, a collection or infection at the injection site, or a reaction or complication related to the particular material. Risks also depend on anaesthesia, previous surgery and the chosen product. Emptying should be checked before discharge. Seek prompt assessment if you cannot pass urine, develop fever, worsening pain or heavy bleeding. [2,4,8]

Choosing a treatment

The first step is to confirm the type and severity of leakage and clarify your goals: complete dryness, meaningful improvement, shorter recovery, avoiding mesh, or avoiding the likelihood of repeat treatment. Pelvic floor therapy remains an initial option. When a procedure is appropriate, we can compare bulking with sling and colposuspension procedures using your examination findings, health history and preferences. If you have already had a sling, the reason for the continuing leakage deserves a fresh assessment before choosing another procedure.

This page is general education, not a recommendation for a particular product or a promise of a result. Treatment, including its material, risks, costs and alternatives, should be discussed during an individual consultation.

References

  1. Urological Society of Australia and New Zealand (USANZ). Surgical Treatment of Stress Urinary Incontinence: Position Statement Pol 054, version 2.0. Approved 9 May 2026.
  2. Urogynaecological Society of Australasia (UGSA). Urethral Bulking: Patient Information.
  3. UGSA. Stress Urinary Incontinence: Patient Resources.
  4. European Association of Urology. Guidelines on Non-neurogenic Female Lower Urinary Tract Symptoms: Disease Management, section 4.2.4.c.2.c.
  5. Itkonen Freitas A-M, et al. Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: a randomised clinical trial. Journal of Urology. 2020.
  6. Itkonen Freitas A-M, et al. Tension-free vaginal tape versus polyacrylamide hydrogel injection for stress urinary incontinence: five-year follow-up. NEJM Evidence. 2025.
  7. Braga A, et al. Urethral bulking agents for the treatment of recurrent stress urinary incontinence: a systematic review and meta-analysis. Maturitas. 2022. doi:10.1016/j.maturitas.2022.05.007.
  8. American Urogynecologic Society. Urethral Bulking: Clinical Practice Statement. Urogynecology. 2024. doi:10.1097/SPV.0000000000001548.